Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Dean

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Pageof 3